PE20040471A1 - Formulaciones de liberacion prolongada en forma de suspension - Google Patents

Formulaciones de liberacion prolongada en forma de suspension

Info

Publication number
PE20040471A1
PE20040471A1 PE2003001065A PE2003001065A PE20040471A1 PE 20040471 A1 PE20040471 A1 PE 20040471A1 PE 2003001065 A PE2003001065 A PE 2003001065A PE 2003001065 A PE2003001065 A PE 2003001065A PE 20040471 A1 PE20040471 A1 PE 20040471A1
Authority
PE
Peru
Prior art keywords
solubilized
prolonged release
suspension
othrene
acetate
Prior art date
Application number
PE2003001065A
Other languages
English (en)
Inventor
Shah Jaymin Chandrakant
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20040471A1 publication Critical patent/PE20040471A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Abstract

SE REFIERE A UN KIT FARMACEUTICO, QUE COMPRENDE: 1)UN COMPUESTO ARILHETEROCICLICO SOLUBILIZADO O NO SOLUBILIZADO, QUE PUEDE SER ZIPRASIDONA; Y, 2)UN VEHICULO LIQUIDO, QUE COMPRENDE UN AGENTE DE VISCOSIDAD, UN TENSIOACTIVO FARMACEUTICAMENTE ACEPTABLE Y EN EL CASO QUE (1) NO ESTE SOLUBILIZADO, COMPRENDE ADEMAS UN AGENTE SOLUBILIZADOR, TAL COMO CICLODEXTRINA. DONDE EL AGENTE DE VISCOSIDAD, ES SELECCIONADO DE: DERIVADOS DE CELULOSA, POLIVINILPIRROLIDONA, ALGINATOS, QUITOSANA, UN DEXTRANO, GELATINA, POLIETILENGLICOLES, ETERES DE POLIOXIETILENO, SUCCINATOS, ACETATO ISOBUTIRATO DE SACAROSA, PLGA, ACIDO ESTEARICO/NMP, ENTRE OTROS O UNA COMBINACION DE LOS MISMOS. SE REFIERE TAMBIEN A UN PROCESO PARA PREPARAR UNA FORMULACION DE LIBERACION PROLONGADA INYECTABLE, QUE COMPRENDE: I)PONER EN CONTACTO (1) Y (2), PARA FORMAR UNA SUSPENSION, CON LA CONDICION YA DESCRITA QUE CUANDO (1) NO ESTA SOLUBILIZADO, (2) CONTIENE ADEMAS UN AGENTE SOLUBILIZADOR; Y EL CONTACTO SE LLEVA A CABO DURANTE UN PERIODO DE TIEMPO SUFICIENTE PARA EFECTUAR LA SOLUBILIZACION DE (1), ANTES DE INYECTAR LA FORMULACION DE LIBERACION PROLONGADA
PE2003001065A 2002-10-25 2003-10-21 Formulaciones de liberacion prolongada en forma de suspension PE20040471A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42129502P 2002-10-25 2002-10-25

Publications (1)

Publication Number Publication Date
PE20040471A1 true PE20040471A1 (es) 2004-08-14

Family

ID=32176696

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003001065A PE20040471A1 (es) 2002-10-25 2003-10-21 Formulaciones de liberacion prolongada en forma de suspension

Country Status (21)

Country Link
US (1) US20040146562A1 (es)
EP (1) EP1562546A1 (es)
JP (2) JP2006505579A (es)
KR (1) KR20050071611A (es)
CN (1) CN1703198A (es)
AR (1) AR041826A1 (es)
AU (1) AU2003267763A1 (es)
BR (1) BR0315663A (es)
CA (1) CA2498276A1 (es)
GT (1) GT200300227A (es)
MX (1) MXPA05004299A (es)
NL (1) NL1024616C (es)
NO (1) NO20051187L (es)
PA (1) PA8586301A1 (es)
PE (1) PE20040471A1 (es)
PL (1) PL375603A1 (es)
RU (1) RU2292207C2 (es)
TW (1) TW200418477A (es)
UY (1) UY28035A1 (es)
WO (1) WO2004037224A1 (es)
ZA (1) ZA200501979B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
US7115587B2 (en) * 2002-08-20 2006-10-03 Bristol-Myers Squibb Company Aripiprazole complex formulation and method
SI2218448T1 (sl) 2002-12-13 2016-01-29 Durect Corporation Sistem za oralno dajanje zdravila, ki obsega tekoči nosilec materialov z visoko viskoznostjo
BRPI0410419A (pt) * 2003-05-16 2006-05-30 Pfizer Prod Inc tratamento para a ansiedade com ziprasidona
WO2006000913A1 (en) * 2004-06-23 2006-01-05 Pfizer Products Inc. Method for sterile filtration of viscous pharmaceutical compositions
KR101351771B1 (ko) 2004-09-17 2014-02-17 듀렉트 코퍼레이션 바람직하게 ｓａｉｂ와 같은 당 에스테르를 포함하는지속적인 국소 마취제 조성물
WO2006096462A1 (en) * 2005-03-03 2006-09-14 Elan Pharma International Limited Nanoparticulate compositions of heterocyclic amide derivatives
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
CN100391458C (zh) * 2006-02-07 2008-06-04 上海医药工业研究院 齐拉西酮或其盐包合物制备方法
NZ572007A (en) * 2006-05-09 2010-12-24 Astrazeneca Ab Parenteral formulation comprising proton pump inhibitor sterilized in its final container by ionizing radiation
PT2117521E (pt) 2006-11-03 2012-09-10 Durect Corp Sistemas de administração transdérmica que compreendem bupivacaína
AU2008347158B8 (en) 2007-12-06 2013-08-22 Durect Corporation Oral pharmaceutical dosage forms
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
EP2983468A4 (en) 2013-03-15 2016-09-07 Durect Corp COMPOSITIONS WITH RHEOLOGY MODIFIER TO REDUCE RESOLUTION VARIABILITY
WO2018153315A1 (zh) 2017-02-23 2018-08-30 上海华汇拓医药科技有限公司 一种多奈哌齐半帕莫酸盐的粉针剂、包含其的组合物及它们的制备方法
WO2021146215A1 (en) 2020-01-13 2021-07-22 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0331755B2 (en) * 1987-09-07 2003-02-05 Teijin Limited Medicine-containing fat emulsion of the type prepared immediately before use and process for preparing medicine-containing fat emulsion
GB9200247D0 (en) * 1992-01-07 1992-02-26 Erba Carlo Spa Pharmaceutical compositions containing polymer derivative-bound anthracycline glycosides and a method for their preparation
JP3954115B2 (ja) * 1992-07-28 2007-08-08 アストラゼネカ・アクチエボラーグ 注射剤および注射剤キット
US5594141A (en) * 1994-11-23 1997-01-14 Neurogen Corporation Certain aminomethyl biphenyl, aminomethyl phenyl pyridine and aminomethyl phenyl pyrimidine derivatives; novel dopamine receptor subtype selective ligands
US6040295A (en) * 1995-01-13 2000-03-21 Genemedicine, Inc. Formulated nucleic acid compositions and methods of administering the same for gene therapy
PT811386E (pt) * 1996-05-07 2004-12-31 Pfizer Metodo de seleccao de um sal para a preparacao de um complexo de inclusao
UA57734C2 (uk) * 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
AU739469B2 (en) * 1996-12-20 2001-10-11 Alza Corporation Gel composition and methods
EA199901013A1 (ru) * 1997-05-16 2000-06-26 Амген Инк. Гели пролонгированного действия
UA72189C2 (uk) * 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
ES2191618T3 (es) * 1999-05-27 2003-09-16 Pfizer Prod Inc Suspension de ziprasidona.
MY137726A (en) * 2000-11-22 2009-03-31 Nycomed Gmbh Freeze-dried pantoprazole preparation and pantoprazole injection
US20030055023A1 (en) * 2001-03-20 2003-03-20 Rajewski Roger A. Formulations containing etomidate and a sulfoalkyl ether cyclodextrin
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
WO2003021225A2 (en) * 2001-08-31 2003-03-13 The Rockefeller University Method for classification of anti-psychotic drugs

Also Published As

Publication number Publication date
EP1562546A1 (en) 2005-08-17
GT200300227A (es) 2004-06-23
UY28035A1 (es) 2004-05-31
KR20050071611A (ko) 2005-07-07
MXPA05004299A (es) 2005-08-03
NL1024616A1 (nl) 2004-04-27
AR041826A1 (es) 2005-06-01
NL1024616C (nl) 2010-04-19
TW200418477A (en) 2004-10-01
JP2006219501A (ja) 2006-08-24
RU2005112202A (ru) 2005-11-20
AU2003267763A1 (en) 2004-05-13
ZA200501979B (en) 2006-04-26
BR0315663A (pt) 2005-08-30
US20040146562A1 (en) 2004-07-29
CN1703198A (zh) 2005-11-30
RU2292207C2 (ru) 2007-01-27
PL375603A1 (en) 2005-12-12
PA8586301A1 (es) 2004-05-07
JP2006505579A (ja) 2006-02-16
WO2004037224A1 (en) 2004-05-06
NO20051187L (no) 2005-04-11
CA2498276A1 (en) 2004-05-06

Similar Documents

Publication Publication Date Title
PE20040471A1 (es) Formulaciones de liberacion prolongada en forma de suspension
PE20040499A1 (es) Nuevas formulaciones de liberacion prolongada inyectables
ES2110377T1 (es) Formulacion galenica de fenofibrato y aplicacion de la misma.
AR033059A1 (es) Preparados de insulina exentos de zinc y pobres en zinc, con estabilidad mejorada.
ATE391708T1 (de) Verbindungen und gemische zur verabreichung eines aktiven agens
CY1120462T1 (el) Τοπικες ανθελμινθικες κτηνιατρικες τυποποιησεις
CR6656A (es) Forma de dosificacion de farmacos accionada por un hidrogel
UY25055A1 (es) Formulaciones farmacéuticas que contienen voriconazol
AR043985A1 (es) Tratamiento terapeutico de la constipacion
DE60105448D1 (de) Feste dispersionen mit nitrataktiven wirkstoffen
DK0762896T3 (da) Tocopherol-sammensætninger til levering af biologisk aktive stoffer
TNSN04249A1 (en) Acidic insulin preparations with improved stability
ES2098739T3 (es) Composiciones oftalmicas conteniendo una cyclosporin.
AR030245A1 (es) Composiciones de gel que contienen metronidazol
WO1999015210A3 (en) Bioadhesive compositions and methods for topical administration of active agents
ATE238813T1 (de) Wirkstoffformulierungen mit verzögerter freisetzung
ATE433746T1 (de) Insulinzusammensetzungen mit verbesserter wirkstoffabsorption
WO2005020962A8 (en) Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs
WO2002019969A3 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
PA8475001A1 (es) Composiciones estabilizadas
ES2184310T3 (es) Formulacion autoemulsionante para compuestos lipofilos acidos.
ATE311373T1 (de) Oxadiazolverbindungen und -zusammensetzungen zur abgabe von wirkstoffen
CL2004000566A1 (es) Sistema de liberacion controlada que contiene un componente farmaceuticamente activo, acetato de isobutirato de sacarosa (saib), y como disolvente glicerolformal o isopropilidenglicerol o una mezcla de los mismos.
SE0102843L (sv) Stabiliserad oral farmaceutisk komposition innehållande jodid och jodat och metod
DE602004005564D1 (de) Pharmazeutische Zusammensetzung für Thrombinpeptidderivaten

Legal Events

Date Code Title Description
FA Abandonment or withdrawal